Close Menu

HER2 Biomarkers

News and reporting on HER2 biomarkers.

NEW YORK (GenomeWeb) – Roche this week announced plans to acquire Seragon Pharmaceuticals, aiming to bolster its own breast cancer pipeline and improve the standard of care for hormone receptor-positive breast cancer.

A new study using gene expression profiling to divide patients from an adjuvant trastuzumab (Herceptin) clinical trial into subgroups based on their response to the drug has shown that adjuvant treatment in addition to chemotherapy might be effective even in HER2-negative patient

The American Society for Clinical Oncology and the College of American Pathologists have jointly issued updated guidelines in which they continued to recommend that oncolo

The US Food and Drug Administration has accepted a supplemental biologics license application for Perjeta (pertuzumab) as a neoadjuvant treatment for women with HER2-positive, early-stage breast cancer, Roche subsidiary Genentech announced this week.

A flurry of recently published peer-reviewed papers has demonstrated the growing breadth and diversity of applications for Bio-Rad's QX100 Droplet Digital PCR system.

Originally published June 3.
CHICAGO – Based on promising results from earlier studies, Pfizer is moving ahead with a Phase III trial to study the investigational agent palbociclib in estrogen receptor-positive, HER2-negative breast cancer patients.

In the first quarter of this year, pharmacogenetically targeted cancer drugs Xalkori and Zelboraf had marked increases in revenues from the previous year's quarter.

NEW YORK (GenomeWeb News) – Biomarker-based diagnostics company Nuclea Biotechnologies today announced a partnership with Wilex aimed at better managing the treatment of metastatic breast cancer.

The US Food and Drug Administration last week approved Roche/Genentech's latest HER2-targeting breast cancer drug, trastuzumab emtansine (T-DM1).

NEW YORK (GenomeWeb News) – Dako today announced that the US Food and Drug Administration has approved its HER2 IQFISH pharmDx assay for marketing in the US.

Pages

Bloomberg Law writes that the Genetic Information Nondiscrimination Act may work better as a privacy, rather than anti-discrimination, law.

TechCrunch reports that Linda Avey has a new personal genomics startup that's focusing on India.

A new report finds that though the US has increased its activity in science and engineering, its global share of that activity has fallen in some areas, according to Inside Higher Ed.

In Nature this week: genomic analysis of rapeseed, universal target enrichment method for metagenomic sequencing, and more.